Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

  title={Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial},
  author={Peter W Marion Jennifer L Louise Natalie Jonathan Adrian Horby Mafham Bell Linsell Staplin Emberson Palfree and Peter W. Horby and Marion M. Mafham and Jennifer L. Bell and Louise Linsell and Natalie Staplin and Jonathan R. Emberson and Adrian Palfreeman and Jason Raw and Einas Elmahi and Benjamin Prudon and Christopher A. Green and Simon Carley and David R. Chadwick and Matthew Davies and Matthew P. Wise and John Kenneth Baillie and Lucy C. Chappell and Saul N. Faust and Thomas F. Jaki and Katie Jefferey and Wei Shen Lim and Alan A. Montgomery and Kathryn M. Rowan and Edmund Juszczak and Richard Haynes and Martin J Landray},
  journal={Lancet (London, England)},
  pages={1345 - 1352}
  • Peter W Marion Jennifer L Louise Natalie Jonathan Adrian Horby Mafham Bell Linsell Staplin Emberson Palfree, P. Horby, M. Landray
  • Published 1 October 2020
  • Medicine
  • Lancet (London, England)

Figures and Tables from this paper

Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Azithromycin use in patients hospitalised with COVID-19 should be restricted to patients where there is a clear antimicrobial indication, and not everyone on invasive mechanical ventilation is likely to be randomised to usual care.

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)

In patients hospitalized for COVID-19, the use of CM was associated with shorter time to clinical improvement, reduced need for MV or death, and shorter LOS than the use with lopinavir/ritonavir or LPV/RTV.

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Among critically ill patients with COVID-19, lopinavir-ritonavir, hydroxychloroquine, or combination therapy worsened outcomes compared to no antiviral therapy, and the three interventions reduced hospital survival compared with control.

An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial

Trough plasma concentrations of lopinavir and ritonavir were higher than those expected, while those of hydroxychloroquine were those expected with the dosing regimen, and the occurrence of Serious Adverse Events was significantly higher in participants allocated to the lOPinavir/ritonavir-containing arms.



A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis

In critically ill patients admitted for SARS-CoV-2-related pneumonia, no difference was found between hydroxychloroquine or lopinavir/ritonavir as compared to standard of care only on the proportion of patients who needed treatment escalation at day 28.

Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients

In mechanically ventilated patients with severe COVID-19 infections, the oral administration of lopinavir/ritonavir elicited plasma exposure of lupinavir more than 6-fold the upper usual expected range, however, it remains difficult to safely recommend its dose reduction without compromising the benefit of the antiviral strategy.

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19

In patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death.

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS and shows that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome.

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

In patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.

Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)

T trough levels of lopinavir and ritonavir are quantified by liquid chromatography–tandem mass spectrometry in patients admitted to a “normal care” ward because of COVID-19, finding that steady-state conditions may be assumed for all patients.

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment

Overall, there was no clear benefit for the use of lopinavir-ritonavir compared to standard of care in severe COVID-19 and the benefit-risk profile cannot be considered positive until further efficacy and effectiveness data become available.

Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in Children

Administration of crushed 200/50 mg lopinavir/ritonavir tablets to children significantly reduced lopvinir and ritonavir exposure with a decrease in AUC by 45% and 47%, respectively.

Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.

Compared with the treatment of pneumonia-associated adjuvant drugs alone, the combination treatment with LPV/r and adjUvant drugs has a more evident therapeutic effect in lowering the body temperature and restoring normal physiological mechanisms with no evident toxic and side effects.